Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence

Maturitas ◽  
2008 ◽  
Vol 60 (2) ◽  
pp. 138-147 ◽  
Author(s):  
Jules H. Schagen van Leeuwen ◽  
Rainer R. Lange ◽  
Aino Fianu Jonasson ◽  
Wei J. Chen ◽  
Lars Viktrup
Keyword(s):  
Urinary Incontinence ◽  
Stress Urinary Incontinence ◽  
Elderly Women ◽  
Mixed Urinary Incontinence ◽  
Efficacy And Safety

scholarly journals Is electroacupuncture safe and effective for treatment of stress urinary incontinence in women? A systematic review and meta-analysis

2020 ◽  
Vol 48 (10) ◽  
pp. 030006052094833
Author(s):  
Xiuhua Lai ◽  
Jiapeng Zhang ◽  
Jing Chen ◽  
Cuiwei Lai ◽  
Chunping Huang
Keyword(s):  
Urinary Incontinence ◽  
Stress Urinary Incontinence ◽  
Elderly Women ◽  
Short Form ◽  
Systematic Evaluation ◽  
Pool Data ◽  
Efficacy And Safety ◽  
International Consultation ◽  
Standard Mean Difference ◽  
Urine Leakage

Objective Stress urinary incontinence (SUI) is prevalent worldwide, particularly among elderly women. Although electroacupuncture (EA) has been accepted by many patients and physicians in Asia, its efficacy for SUI has not been evaluated scientifically and systematically. We aimed to conduct a systematic evaluation of the efficacy and safety of EA treatment for women with SUI. Methods We retrieved publications up to February 2019 from seven databases. Randomized controlled trials for women with SUI treated by EA were included. Therapeutic effect, 1-hour urine leakage and International Consultation on Incontinence Questionnaire – Short Form (ICIQ-SF) scores were the primary outcomes. The Cochrane Collection’s RevMan 5.3 software was used to pool data. Results The 15 included articles demonstrated that EA for SUI was effective (odds ratio [OR], confidence interval [CI] = 5.64, 4.19–7.59; Ι2 = 22%). ICIQ-SF scores increased (standard mean difference, CI = −0.48, −0.62 to −0.33; Ι2 = 32%) and 1-hour urine leakage decreased (OR, CI = −4.14, −4.96 to −3.33; Ι2 = 78%) in patients undergoing EA compared with those receiving sham EA, physical exercise or medication. Conclusion EA for women with SUI exhibited significant efficacy and safety for key outcomes.

scholarly journals The impact of pelvic floor muscle training on the myostatin concentration and severity of urinary incontinence in elderly women with stress urinary incontinence – a pilot study

2018 ◽  
Vol Volume 13 ◽  
pp. 1893-1898 ◽  
Author(s):  
Agnieszka Radzimińska ◽  
Magdalena Weber-Rajek ◽  
Agnieszka Strączyńska ◽  
Marta Podhorecka ◽  
Mariusz Kozakiewicz ◽  
...  
Keyword(s):  
Urinary Incontinence ◽  
Pilot Study ◽  
Stress Urinary Incontinence ◽  
Pelvic Floor ◽  
Elderly Women ◽  
Pelvic Floor Muscle Training ◽  
Pelvic Floor Muscle ◽  
Muscle Training ◽  
The Impact

scholarly journals A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients

Toxins ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 365 ◽  
Author(s):  
Yi-Huei Chang ◽  
Po-Jen Hsiao ◽  
Huang Chi-Ping ◽  
Hsi-Chin Wu ◽  
Po-Fan Hsieh ◽  
...  
Keyword(s):  
Urinary Incontinence ◽  
Botulinum Toxin ◽  
Adverse Events ◽  
Observational Study ◽  
Botulinum Toxin A ◽  
Mixed Urinary Incontinence ◽  
Efficacy And Safety ◽  
Toxin A ◽  
Antimuscarinic Agent ◽  
Significant Difference

This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence. This was a comparative observational study, and total of 73 patients were enrolled. A total of 38 and 35 patients received MUS only and MUS with BoNT-A injection, respectively. The efficacy outcome included change in Urinary Incontinence Outcome Scores (UIOS), change in Overactive Bladder Symptom Score (OABSS), and use of antimuscarinic agent or beta-3 agonist. Safety assessments included adverse events including urinary retention, increased postvoid residual volumes, and urinary tract infection. MUS with BoNT-A injection was insignificantly better than MUS only in urinary incontinence outcome (88% vs. 71%, respectively, p = 0.085) at week three. Among the 33 patients with detrusor overactivity (DO), patients who received BoNT-A had a higher cure rate of incontinence (88% vs. 41%, p = 0.01) and less required antimuscarinic agent or beta-3 agonist (31% vs. 94%, p < 0.001) compared to patients who did not receive BoNT-A injection. There was no significant difference in the incidences of adverse events between two groups. BoNT-A injection with MUS demonstrated efficacy and safety in the treatment of mixed urinary incontinence, specifically for women with DO.

Sign in / Sign up

Export Citation Format

Share Document